Main > ONCOLOGY (**) > Breast Cancer>HER2+>MET *** > Treatment > USA. P. Neratinib+Capecitabine>

---

USA. P. Neratinib+Capecitabine>'s subsections
(*) USA Approval Date: 2020. 02.26.
>2 Prior Anti-HER2-based Regimens
Company
Patent>Assignee; Claims; No.; Etc.
TradeMark Capecitabine
TradeMark Neratinib
TradeMark Neratinib Web-Site

USA. P. Neratinib+Capecitabine>'s products
This section has no products